Compass Pathways Wave Analysis: Huge Moves aheadCompass Pathways appears to have completed an impulsive 5-wave move to the upside, signaling significant strength in its recent price action. The peak of this move, reaching $12.75, is notably identified as the B wave within an extended flat correction, potentially forming part of a larger 5-wave pattern.
In anticipation of a corrective phase, I anticipate a retracement towards the 0.618 - 0.65 Fibonacci ratio. This level coincides with a point of demand established in May 2022, which has historically served as a robust support level. Therefore, I am targeting a correction to the range of $6.86-7.06, presenting a compelling buying opportunity. This represents a potential decrease of approximately 30.7% to 29.1% from the current price of $9.90.
Looking ahead, my projections for subsequent waves are as follows:
Low: $21.07 (+112.8%)
Medium: $29.68 (+199.8%)
High: $41.80 (+322.2%)
Moonshot: $120 (+1,111.1%)
It's essential to note that the realization of these targets will be contingent upon the outcome of Compass Pathways' significant psilocybin phase 3 trial, slated for release by year-end. Regardless of the trial's results, I anticipate a substantial increase in price leading up to the release date, driven by market anticipation and sentiment.
In summary, while Compass Pathways demonstrates considerable strength in its recent price movements, caution is advised as the stock may undergo a corrective phase towards identified support levels before potentially resuming its upward trajectory, influenced by the impending trial results.
